QLT0267, a small molecule inhibitor targeting integrin-linked kinase (ILK), and docetaxel can combine to produce synergistic interactions linked to enhanced cytotoxicity, reductions in P-AKT levels, altered F-actin architecture and improved treatment outcomes in an orthotopic breast cancer model

Table 2 Synergy, antagonism, and additivity in LCC6 and LCC6Her2 cells treated with QLT0267 in combination with several clinically relevant agents

Chemotherapeutic agent	Drug concentration range	QLT0267: Drug ratio (nM)¹	Result²
Cisplatin	0.15 to 20.0 μM	1, 2, 4: 1	Antagonistic at all ratios
Doxorubicin	0.0625 to 2.0 μM	10, 20, 40: 1	Antagonistic at all ratios
Paclitaxel	0.313 to 15.0 nM	1000, 4000:1	Antagonistic at all ratios
Vinorelbine	0.0625 to 4.0 nM	10,000, 20,000, 40,000: 1	Antagonistic at all ratios
Docetaxel	0.125 to 1.0 nM	50,000, 95,000: 1	Synergistic at all ratios
Trastuzumab	3.1 × 10^-7 to 1 mg/ml	50,000: 1 mg/ml	Variable

¹ Drug ratios were chosen based on effective dose values of single agent treatment.
² Synergy is defined as a combination that exhibits combination index values of less then one at high affect levels over a minimum of four drug concentrations.

ISSN: 1465-542X